PE Tech Report


Like this article?

Sign up to our free newsletter

HIG Capital acquires BioVectra

An affiliate of private equity investment firm HIG Capital (HIG) has completed the acquisition of BioVectra, a contract development and manufacturing organisation (CDMO) of active pharmaceutical ingredients and intermediates.

Founded in 1970, BioVectra’s core competencies include microbial fermentation, complex chemistry, high potency, and biologics. They impact the lives of patients by producing products that are used to treat cancer, kidney disease, cardiovascular disease, multiple sclerosis, and many other complex diseases. The Company is strategically located in Canada with over 110,000 sq ft of manufacturing space uniquely designed to support its biopharmaceutical clients from the early stages of clinical development to scale-up and commercial manufacturing.

“We are very pleased to partner with Oliver Technow as well as his exceptional leadership team and dedicated employees,” says Mike Gallagher, Managing Director at HIG Capital. “Oliver and his team have expanded BioVectra’s presence by pursuing strategic capital expenditure programs to significantly expand capacity. We believe the Company is well positioned to capitalize on the growing demand for its broad set of technical capabilities and exceptional quality track record.”

“We are excited to enter into this new chapter with HIG Capital,” Says Oliver Technow, Chief Executive Officer of BioVectra. “We have been fortunate over the last few years with the support of Mallinckrodt Pharmaceuticals to execute on our strategic growth plan. We look ahead to continuing on this path with HIG Capital, an experienced investor in the CDMO space. HIG is committed to our strategy and management team, and we look forward to continuing to pursue the Company’s various growth initiatives.”

Like this article? Sign up to our free newsletter